AngioDynamics (NASDAQ: ANGO) is a medical technology company that develops and sells devices for the treatment of cardiovascular disease and cancer. Revenue is generated through transactional product sales of single-use and capital medical devices to hospitals and clinicians, with rebates and allowances reducing net revenue in the period earned. The company operates two reporting segments and concentrates its investment on three product platforms: Auryon (atherectomy), Mechanical Thrombectomy (including AngioVac and AlphaVac), and NanoKnife (irreversible electroporation tissue ablation). Recent regulatory milestones include CE mark approval in Europe for Auryon, FDA 510(k) clearance for NanoKnife Prostate Tissue Ablation, and CPT Category I Codes for Irreversible Electroporation procedures effective January 2026, per the FY2025 10-K filed July 18, 2025. The company has a settlement and license agreement with Becton, Dickinson and Company, C.R. Bard, and Bard Peripheral Vascular dated March 31, 2024. Products are subject to Medicare, Medicaid, and private third-party payer reimbursement dynamics under U.S. federal and state health care laws.

Revenue model

Transactional product sales of medical devices, net of rebates, allowances, and an estimated product return reserve recorded as contra-revenue. Product returns after 30 days require pre-approval and may carry a 20% restocking charge.

Products and services

Auryon atherectomy system; AngioVac and AlphaVac mechanical thrombectomy devices; NanoKnife irreversible electroporation system for tissue ablation (prostate and liver indications).

Customers and end markets

Hospitals and clinicians treating cardiovascular disease and cancer. Reimbursement is tied to Medicare, Medicaid, and private third-party payers. End markets include interventional cardiology, peripheral vascular intervention, and oncology ablation.

Value-chain role

Medical device manufacturer and seller; relies on third-party contract manufacturers for production. Sells direct to clinical end users.

Geographic exposure

Primarily United States; international operations present, including CE mark approval in Europe for Auryon. International manufacturing relationships subject to FCPA compliance requirements.

Source: SEC 10-K, filed 2025-07-18

Industry: Surgical & Medical Instruments & Apparatus Peers: Abbott Laboratories Alphatec Holdings Inc CUTERA INC Senseonics Holdings Inc Butterfly Network Inc HESKA CORP Outset Medical Inc Mesa Laboratories Inc ViewRay, Inc. Varex Imaging Corp